TITLE

High frequency of early colorectal cancer in inflammatory bowel disease

AUTHOR(S)
Lutgens, M. W. M. O.; Vleggaar, F. P.; Schipper, M. E. I.; Stokkers, P. C. F.; Van Der Woude, C. J.; Hommes, D. W.; De Jong, D. J.; Dijkstra, G.; Van Bodegraven, A. A.; Oldenburg, B.; Samsom, M.
PUB. DATE
September 2008
SOURCE
Gut;Sep2008, Vol. 57 Issue 9, p1246
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aim: To detect precancerous dysplasia or asymptomatic cancer, patients suffering from inflammatory bowel disease often undergo colonoscopic surveillance based on American or British guidelines. It is recommended that surveillance is initiated after 8-10 years of extensive colitis, or after 15-20 years for left-sided disease. These starting points, however, are not based on solid scientific evidence. Our aim was to assess the time interval between onset of inflammatory bowel disease (IBD) and colorectal carcinoma (CRC), and subsequently evaluate how many patients developed cancer before their surveillance was recommended to commence. Methods: A nationwide automated pathology database (PALGA) was consulted to identify patients with IBD- associated colorectal carcinoma in seven university medical centres in The Netherlands between January 1990 and June 2006. Data were collected retrospectively from patient charts. Time intervals between onset of disease and cancer diagnosis were calculated in months. Results: 149 patients were identified with confirmed diagnoses of IBD and CRC (ulcerative colitis n = 89/Crohn's disease n = 59/indeterminate colitis n = 1). Taking date of diagnosis as the entry point, 22% of patients developed cancer before the 8 or 15 year starting points of surveillance, and 28% if surveillance was commenced 10 or 20 years after diagnosis for extensive or left-sided disease, respectively. Using onset of symptoms to calculate the time interval, 17-22% of patients would present with cancer prior to the surveillance starting points. Conclusions: These results show that the diagnosis of colorectal cancer is delayed or missed in a substantial number of patients (17-28%) when conducting surveillance strictly according to formal guidelines.
ACCESSION #
34310411

 

Related Articles

  • Colorectal cancer and dysplasia in inflammatory bowel disease. Zisman, Timothy L.; Rubin, David T.; Marshall, John K. // World Journal of Gastroenterology;5/7/2008, Vol. 14 Issue 17, p2662 

    Both ulcerative colitis and Crohn's disease carry an increased risk of developing colorectal cancer. Established risk factors for cancer among patients with inflammatory bowel disease (IBD) include the younger age at diagnosis, greater extent and duration of disease, increased severity of...

  • Is Colonoscopy Alone Sufficient to Screen for Ulcerative Colitis-associated Colorectal Carcinoma? World J. Surg. Vol. 27, No. 5, May 2003. Bruewer, Matthias; Krieglstein, Christian F.; Utech, Markus; Bode, Marc; Rijcken, Emile; Anthoni, Christoph; Laukoetter, Mike G.; Schuermann, Guido; Senninger, Norbert // World Journal of Surgery;May2003, Vol. 27 Issue 5, p611 

    Patients with ulcerative colitis (UC) are at increased risk for colorectal carcinoma (CAC). Despite the fact that patients at risk are followed closely by colonoscopy to screen for dysplasia, the prevalence of CAC is still unacceptably high. The aim of this study was to evaluate the prevalence...

  • An Updated Approach to Dysplasia in IBD. Rubin, David T. // Journal of Gastrointestinal Surgery;Dec2008, Vol. 12 Issue 12, p2153 

    Introduction Long-standing inflammation of the colorectum in ulcerative colitis (UC) and Crohn's disease (CD) has been associated with an increased risk of subsequent dysplasia and colorectal cancer. Historically, it was described that the neoplastic transformation in these inflammatory bowel...

  • Dysplasia in ulcerative colitis-clinical consequences? Sjöqvist, Urban // Langenbeck's Archives of Surgery;Oct2004, Vol. 389 Issue 5, p354 

    Background: The overall absolute risk of colorectal cancer (CRC) in longstanding extensive or total ulcerative colitis (UC) is estimated to be 10%-15%. The size of this risk is 6- to 10-times that expected in the background population. By performing complete colonoscopies with multiple biopsies...

  • The management of dysplasia associated with ulcerative colitis: colectomy versus continued surveillance. Friedlich, Martin S.; Guindi, Maha; Stern, Hartley S. // Canadian Journal of Surgery;Jun2004, Vol. 47 Issue 3, p212 

    The article focuses on the management of dysplasia associated with ulcerative colitis (UC). Colectomy versus continued surveillance in patients with longstanding UC is a challenging decision. Several factors must be considered. Often such patients have quiescent disease, making the prospect of...

  • Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis. van der Woude, C. J.; Moshage, H.; Homan, M.; Kleibeuker, J. H.; Jansen, P. L. M.; van Dekken, H. // Journal of Clinical Pathology;Aug2005, Vol. 58 Issue 8, p811 

    Background: Chronic ulcerative colitis (CUC) is associated with increased risk of developing colon cancer through a dysplasia (intraepithelial neoplasia)-carcinoma sequence. Aims: To investigate the expression of apoptosis and inflammatory related proteins in CUC. Methods: The expression of...

  • Chromoendoscopy for Surveillance in Inflammatory Bowel Disease Does Not Increase Neoplasia Detection Compared With Conventional Colonoscopy With Random Biopsies: Results From a Large Retrospective Study. Mooiweer, E; van der Meulen-de Jong, A E; Ponsioen, C Y; Fidder, H H; Siersema, P D; Dekker, E; Oldenburg, B // American Journal of Gastroenterology;Jul2015, Vol. 110 Issue 7, p1014 

    Objectives:Randomized trials demonstrated that chromoendoscopy is superior to white light endoscopy with random biopsy sampling (WLE) for the detection of dysplasia in patients with inflammatory bowel disease (IBD). Whether implementing chromoendoscopy can increase the detection of dysplasia in...

  • Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Lutgens, M. W. M. D.; Oldenburg, B.; Siersema, P. D.; van Bodegraven, A. A.; Dijkstra, G.; Hommes, D. W.; de Jong, D. J.; Stokkers, P. C. F.; van der Woude, C. J.; Vleggaar, F. P. // British Journal of Cancer;11/17/2009, Vol. 101 Issue 10, p1671 

    Background:Colonoscopic surveillance provides the best practical means for preventing colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients. Strong evidence for improved survival from surveillance programmes is sparse.Method:The aim of this study was to compare tumour stage and...

  • Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Marelli, Laura; Xirouchakis, Elias; Kalambokis, Georgios; Cholongitas, Evangelos; Hamilton, Mark I.; Burroughs, Andrew K. // Gut;Sep2011, Vol. 60 Issue 9, p1224 

    Background and aims Ulcerative colitis (UC) associated with primary sclerosing cholangitis (PSC) is usually clinically mild. The aim of the study was to assess whether there is an association between severity of PSC and activity of UC, comparing the course of UC in patients with PSC not needing...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics